Funding profile · Consumer longevity services

Forever Labs

One disclosed round, in 2018, and nothing in SEC EDGAR under the company name. Whatever capital the business has taken since is not in the public record, and its only revenue figure is six years old.

$2.0MAnnounced financing, May 10, 2018, the only round the company has ever disclosed
$2.22MTotal across three seed rounds, per a startup database, not a filing
0SEC filings of any type found under the name Forever Labs
~1,000Clients banked as of Nov 2020, company-stated, never updated

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Aug 2017 Seed Not disclosed Y Combinator, Summer 2017 batch Startup database
Oct 2017 Seed Not disclosed BABEL Ventures, recorded as first investing on this date Startup database
May 10, 2018 Seed, announced $2,000,000 Northwestern Mutual, Silicon Badia Ventures, Babel Ventures, Aaron Hirschhorn, and physicians Michael Dobryansky, Timothy Davis and Michael Schenden Company release
2018 to 2026 Nothing announced None disclosed None disclosed Not found
May 8, 2025 SuperShot Inc. spun out; Kevin Virgil appointed CEO No capital disclosed Not stated Company release
Cumulative All rounds $2.22M 13 investors, 9 institutional and 4 angels, per the same database Startup database

What the filings show

SEC EDGAR full text search · run Sep 23, 2026

Query
“Forever Labs” as an exact phrase, all forms, all dates
Result
0 hits
Variant
“Forever Labs, Inc” returned 0 hits
Company search
EDGAR company name search for “forever labs” returned no matching companies
Control check
The same queries return hits for other private issuers
Meaning
No Form D, no Form C, no Form C-AR and no CIK under this name

Regulation Crowdfunding check · Forms C and C-AR

Why it matters
A Form C carries issuer financial statements; a Form C-AR carries an annual update
Result
No Form C or Form C-AR found under the company name
Reviewed financials
None in the public record
Coverage
Individual investors named in press coverage, no portal offering on file

Reading the filings

  1. Silence in EDGAR is not proof that no money moved.An issuer that sells securities under Section 4(a)(2) rather than Regulation D files no Form D at all. The absence tells you the company has not used the exemptions that create a public paper trail. It does not tell you the cap table.
  2. The only confirmed number is eight years old.$2,000,000, announced May 10, 2018, named investors, no filing to corroborate it. Every capital event since has gone unannounced.
  3. The database total and the press release nearly agree.A startup database records $2.22M across three seed rounds. Subtract the announced $2.0M and roughly $220,000 is left for the two 2017 rounds, the shape of a Y Combinator investment plus a small angel round. It is also the weakest evidence on this page.
  4. The revenue math is small.About 1,000 clients at the $250 annual storage fee quoted in 2020 is about $250,000 a year in recurring storage revenue, before collection fees and before any client on the lifetime plan. Asked in that interview whether recurring revenue was enough to run the business, the CEO said: “There’s enough to run the business.” No figure has been published since.
  5. Control changed without a financing.In May 2025 the board replaced the founding CEO and the founders left to run a spun out platelet-rich plasma company, with no round announced alongside it. A board that can do that has outside members, which is consistent with the 2018 investor list.
  6. The business model changed too.The current CEO describes a move from a biobank into a regenerative manufacturing platform, and the company says it is building a cGMP-compliant facility for cell expansion. That is a capital-intensive change of direction being funded from somewhere the public record does not show.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance, approval or biologics license. A query of the FDA Human Cell and Tissue Establishment Registration database on Sep 23, 2026 for any establishment named Forever returned no records. Public record
Intellectual property Five US patents assigned to Forever Labs, Inc., granted Apr 2021 to Apr 2026, inventors Mark Katakowski and Ann Hozeska-Solgot. Public record
Pricing Annual and lifetime memberships. No headline price is published; the site shows financing examples of $83 and $278 a month over 36 payments at zero percent, implying about $2,988 and about $10,008. Company-stated
Distribution A published network of 16 named physicians across 10 states and DC, plus a June 2026 partnership with AcCELLerated Biologics of Jupiter, Florida. Company-stated
Regulatory tailwind claimed Florida SB 1768, effective July 1, 2025, permits marketing of stem cell therapies the FDA has not approved for orthopedics, wound care and pain management, and requires an FDA-registered facility accredited by NMDP, WMDA, AABB or AATB. Public record
Clinical evidence No registered trial and no peer-reviewed publication by the company. Not found

What to watch

  • A first Form D under the company name. One would be due within 15 days of a first sale in any Regulation D offering.
  • Any disclosure of how the laboratories and the planned cGMP facility are being paid for.
  • An updated client or revenue number, the first since November 2020.
  • Whether the company appears in the FDA tissue establishment register, and whether it obtains AABB or AATB accreditation.
  • Whether SuperShot Inc., now run by both founders, raises separately and files.

The Forever Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • dNovo: Also in Therapeutics. A Stanford trained biologist's direct reprogramming system once grew human hair on the backs of lab mice
  • Entelexo Biotherapeutics: Also in Therapeutics. An Irvine company engineering exosomes into drug candidates for autoimmune disease, built on published UC Irvine research
  • Dorian Therapeutics: Also in Therapeutics. A Stanford spinout that built small molecule blockers of USP16, the enzyme that strips a silencing mark off histone H2A, and pointed them at the arthritic knee
  • Guardian Bio: Also in Therapeutics. A Boston biotech built a platform to grow a rare, potent dendritic cell from a cancer patient’s own stem cells and train it against that patient’s tumor

Sources

  1. Public recordSEC EDGAR full text search and company name search for Forever Labs, zero resultsSEC · Sep 23, 2026
  2. Public recordFDA tissue establishment registration query, name Forever, no recordsFDA CBER · Sep 23, 2026
  3. Public recordPatents assigned to FOREVER LABS, INC., five grantsJustia Patents · accessed Sep 23, 2026
  4. Public recordClinicalTrials.gov search for Forever Labs, zero studiesNLM · Sep 23, 2026
  5. IndependentNew Florida Law Attempts to Provide Leeway for Certain Stem Cell TreatmentsHolland & Knight · Aug 18, 2025
  6. Startup databaseForever Labs funding rounds and investor listTracxn · accessed Sep 23, 2026
  7. InterviewYC-backed stem cell banking, interview with Steven ClausnitzerMixergy, Andrew Warner · Nov 6, 2020
  8. IndependentTech workers are paying $7,000 to freeze their stem cellsCNBC · May 4, 2018
  9. IndependentForever Labs Secures $2 Million For Stem Cell BankingBiobanking.com, David Orchard-Webb · May 15, 2018
  10. CompanyForever Labs Receives $2M, investor list and founder statementsVC News Daily · May 10, 2018
  11. CompanyForever Labs Announces Spinout of SuperShot Inc. and Appoints New CEOPR Newswire, via BioSpace · May 8, 2025
  12. CompanyAcCELLerated Biologics Announces Strategic Partnership with Forever LabsPR Newswire · June 9, 2026
  13. CompanyForever Labs website: services, science, provider network, CEO pageforeverlabs.com · Sep 23, 2026

Compiled from SEC, FDA, USPTO and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; no such notice was found for this company, and companies that raise under Section 4(a)(2) file none. Healthcare Venture Capital Fund holds no position in Forever Labs. This page is not an offer to sell or a recommendation to buy any security.